Published in Biotechnol Bioeng on March 30, 2004
Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle (2011) 2.80
Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells (2011) 2.75
Subversion of autophagy by Kaposi's sarcoma-associated herpesvirus impairs oncogene-induced senescence. Cell Host Microbe (2012) 1.82
Oncolytic reovirus against ovarian and colon cancer. Cancer Res (2002) 1.73
p21Cip1/WAF1 mediates cyclin B1 degradation in response to DNA damage. Cell Cycle (2009) 1.60
Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res (2003) 1.59
Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A (2004) 1.53
Reovirus oncolysis of human breast cancer. Hum Gene Ther (2002) 1.45
Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem (2002) 1.44
Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci U S A (2002) 1.28
Reovirus therapy of lymphoid malignancies. Blood (2002) 1.28
Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther (2009) 1.27
Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther (2011) 1.24
DNA damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. EMBO J (2002) 1.21
Ex vivo expansion of human mesenchymal stem cells in defined serum-free media. Stem Cells Int (2012) 1.20
Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res (2010) 1.19
The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet? Cell Cycle (2010) 1.17
Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther (2010) 1.13
Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res (2004) 1.11
Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene (2005) 1.10
Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res (2003) 1.07
p53 Binding to the p21 promoter is dependent on the nature of DNA damage. Cell Cycle (2008) 1.04
Human mast cell activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by a CXCL8-dependent mechanism. Blood (2008) 1.03
New tissue dissociation protocol for scaled-up production of neural stem cells in suspension bioreactors. Tissue Eng (2004) 1.03
DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. Oncotarget (2011) 1.01
Spinal GABAergic transplants attenuate mechanical allodynia in a rat model of neuropathic pain. Stem Cells (2007) 1.01
Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol Ther (2012) 0.99
Scale-up of breast cancer stem cell aggregate cultures to suspension bioreactors. Biotechnol Prog (2006) 0.99
Estimation in Bayesian disease mapping. Biometrics (2004) 0.97
Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Res (2003) 0.94
Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today (2005) 0.93
DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage. J Biol Chem (2004) 0.93
Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells. DNA Repair (Amst) (2007) 0.91
Cell cycle kinetics of expanding populations of neural stem and progenitor cells in vitro. Biotechnol Bioeng (2004) 0.91
Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells. Cytotherapy (2010) 0.90
Large-scale production of human mesenchymal stem cells for clinical applications. Biotechnol Appl Biochem (2013) 0.89
UV-dependent alternative splicing uncouples p53 activity and PIG3 gene function through rapid proteolytic degradation. J Biol Chem (2004) 0.89
Chromium-mediated apoptosis: involvement of DNA-dependent protein kinase (DNA-PK) and differential induction of p53 target genes. DNA Repair (Amst) (2008) 0.89
Expansion of mammalian neural stem cells in bioreactors: effect of power input and medium viscosity. Brain Res Dev Brain Res (2002) 0.87
A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J Urol (2004) 0.86
Ras transformation results in cleavage of reticulon protein Nogo-B that is associated with impairment of IFN response. Cell Cycle (2015) 0.85
Scaled-up production of mammalian neural precursor cell aggregates in computer-controlled suspension bioreactors. Biotechnol Bioeng (2006) 0.84
Genotoxic agents promote the nuclear accumulation of annexin A2: role of annexin A2 in mitigating DNA damage. PLoS One (2012) 0.84
Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis. J Virol (2012) 0.84
Expansion of human neural precursor cells in large-scale bioreactors for the treatment of neurodegenerative disorders. Biotechnol Prog (2009) 0.83
Human mesenchymal stem cell culture: rapid and efficient isolation and expansion in a defined serum-free medium. J Tissue Eng Regen Med (2011) 0.83
Genomic organization and functional expression of differentially regulated cysteine protease genes of Leishmania donovani complex. Gene (2002) 0.83
Dynamic behavior of cells within neurospheres in expanding populations of neural precursors. Brain Res (2006) 0.82
A review of bioreactor protocols for human neural precursor cell expansion in preparation for clinical trials. Curr Stem Cell Res Ther (2011) 0.82
Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis. PLoS One (2013) 0.82
Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture. Methods Mol Biol (2012) 0.81
Ras signalling pathway: a gateway for HSV-1 infection. ScientificWorldJournal (2003) 0.80
Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural/glial proliferation and differentiation. Stem Cell Rev (2015) 0.80
Large-scale expansion of mammary epithelial stem cell aggregates in suspension bioreactors. Biotechnol Prog (2005) 0.80
Bioreactor expansion of human neural precursor cells in serum-free media retains neurogenic potential. Biotechnol Bioeng (2010) 0.79
Production of islet-like structures from neonatal porcine pancreatic tissue in suspension bioreactors. Biotechnol Prog (2006) 0.79
Passaging protocols for mammalian neural stem cells in suspension bioreactors. Biotechnol Prog (2002) 0.78
Transplantation of GABAergic cells derived from bioreactor-expanded human neural precursor cells restores motor and cognitive behavioral deficits in a rodent model of Huntington's disease. Cell Transplant (2012) 0.77
Viral subversion of autophagy impairs oncogene-induced senescence. Autophagy (2012) 0.77
Bioprocessing of human glioblastoma brain cancer tissue. Tissue Eng Part A (2010) 0.77
Survival, differentiation, and migration of bioreactor-expanded human neural precursor cells in a model of Parkinson disease in rats. Neurosurg Focus (2008) 0.76
Characterization of human islet-like structures generated from pancreatic precursor cells in culture. Biotechnol Bioeng (2006) 0.76
New bioengineering insights into human neural precursor cell expansion in culture. Biotechnol Prog (2011) 0.76
Lymphomas and oncolytic virus therapy. Clin Lymphoma (2003) 0.76
If cancer stem cells are resistant to current therapies, what's next? Future Oncol (2009) 0.75
Statistical methods for active pharmacovigilance, with applications to diabetes drugs. J Biopharm Stat (2014) 0.75
Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis in vivo. Antivir Ther (2010) 0.75